duloxetine hydrochloride + pregabalin + gabapentin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diabetic Neuropathy, Painful
Conditions
Diabetic Neuropathy, Painful
Trial Timeline
Sep 1, 2006 → Nov 1, 2009
NCT ID
NCT00385671About duloxetine hydrochloride + pregabalin + gabapentin
duloxetine hydrochloride + pregabalin + gabapentin is a approved stage product being developed by Eli Lilly for Diabetic Neuropathy, Painful. The current trial status is completed. This product is registered under clinical trial identifier NCT00385671. Target conditions include Diabetic Neuropathy, Painful.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00385671 | Approved | Completed |
Competing Products
20 competing products in Diabetic Neuropathy, Painful